[an error occurred while processing this directive]

Journal of Chinese Integrative Medicine ›› 2011, Vol. 9 ›› Issue (8): 857-865.doi: 10.3736/jcim20110807

• Original Clinical Research • Previous Articles     Next Articles

Development of a patient-reported outcome scale for stable chronic obstructive pulmonary disease and its clinical applicability

Yan-bo Zhu1(), You-lin Li2(), Wei Wang3, Fang-chao Jiang2   

  1. 1. School of Administration, Beijing University of Chinese Medicine, Beijing 100029, China
    2. Department of Respiration, China-Japan Friendship Hospital, Beijing 100029, China
    3. Postgraduate School, Beijing University of Chinese Medicine, Beijing 100029, China
  • Received:2011-02-01 Accepted:2011-03-25 Online:2011-08-20 Published:2011-08-15

RichHTML

2

PDF (PC)

341

Like

Objective: To develop a patient-reported outcome (PRO) scale for patients with stable chronic obstructive pulmonary disease (sCOPD) and to study its clinical applicability in traditional Chinese medicine (TCM).
Methods: According to standardized procedures, the test version of PRO scale for sCOPD (sCOPD-PRO scale) was developed based on the theory of “unity of body and spirit” and was used to test 324 patients selected from six clinical centers. Five methods were used to analyze the items; the reliability, validity and responsiveness of the remaining items of the scale were evaluated.
Results: (1) sCOPD-PRO consisted of 23 items after item analysis, and according to the content of each item, these items could be grouped into four domains, namely, lung and kidney deficiency symptom, spleen deficiency symptom, functional activities and emotional impact. (2) Cronbach’s alpha coefficient for sCOPD-PRO scale was more than 0.75 in four domains and total scores. (3) sCOPD-PRO scale and St. George’s Respiratory Questionnaire (SGRQ) were moderately correlated or highly correlated in corresponding domains: the correlation coefficient between the total score of sCOPD-PRO scale and the total score of SGRQ was 0.72 (P<0.01), the correlation coefficient between functional activities domain of sCOPD-PRO scale and activity domain of SGRQ was 0.77 (P<0.01), and the correlation coefficient between emotional impact domain of sCOPD-PRO scale and impact domain of SGRQ was 0.51 (P<0.01). Factor analysis revealed that four factors could explain 65.06% of the total variance. (4) The four domains and total scores of sCOPD-PRO scale were significantly different before and after intervention in TCM group and Western medicine group (P<0.01); moreover, the effect size and standardized response mean of two groups were more than 0.4.
Conclusion: The development process and method of sCOPD-PRO scale, which is based on the theories of “unity of body and spirit”, are standard, and the reliability, validity and responsiveness of the scale are sound and can be relied upon for sCOPD clinical efficacy evaluation of TCM.

Key words: pulmonary disease,chronic obstructive, program evaluation, patient-reported outcome, controlled clinical trial

Table 1

General characteristics of research objects among different groups"

Variable TCM group (n=106) Western medicine group
(n=106)		 Placebo group
(n=107)		 Statistical value P value
Age (x±s, years) 62.05±9.96 62.75±10.00 63.52±8.22 0.65 0.52
Gender 0.68 0.71
Male (n, %) 73 (66.87) 78 (73.58) 78 (72.90)
Female (n, %) 33 (31.13) 28 (26.42) 29 (27.10)
Marital status 2.02 0.37
Married (n, %) 106 (100.00) 105 (99.06) 107 (100.00)
Unmarried (n, %) 0 (0.00) 1 (0.94) 0 (0.00)
Culture degree 6.86 0.55
Elementary school or below (n, %) 11 (10.38) 13 (12.26) 13 (12.14)
Junior high school (n, %) 41 (38.68) 36 (33.96) 27 (25.23)
High school (n, %) 27 (25.47) 34 (32.08) 40 (37.38)
University (n, %) 26 (24.53) 23 (21.70) 26 (24.30)
Master degree or above (n, %) 1 (0.94) 0 (0.00) 1 (0.93)
COPD classification 0.14 0.93
Mild (n, %) 5 (4.72) 6 (5.66) 5 (4.67)
Moderate (n, %) 101 (95.28) 100 (94.34) 102 (95.33)

Table 2

Summary of five methods which were used to screen items"

Item Item
distribution		 Related coefficient
method		 Cronbach’s alpha
coefficient method		 Factor analysis
method		 Subjective evaluation
method		 Elected
frequency		 Remained
item
1 √ √ 2
2 √ √ √ 3
3 √ √ √ √ √ 5 √
4 √ √ √ √ √ 5 √
5 √ √ √ √ √ 5 √
6 √ √ √ √ √ 5 √
7 √ √ 2
8 √ 1
9 √ √ √ √ √ 5 √
10 √ √ √ √ √ 5 √
11 √ √ 2
12 √ √ √ 3
13 √ √ 2
14 √ √ √ √ 4 √
15 √ √ √ √ 4 √
16 √ √ 2
17 √ √ √ √ √ 5 √
18 √ √ √ √ √ 5 √
19 √ √ √ √ √ 5 √
20 √ √ √ √ 4 √
21 √ √ √ √ 4 √
22 √ √ √ √ √ 5 √
23 √ √ √ √ √ 5 √
24 √ √ √ √ √ 5 √
25 √ √ √ √ √ 5 √
26 √ 1
27 √ √ √ √ √ 5 √
28 √ √ 2
29 √ 1
30 √ √ √ √ √ 5 √
31 √ √ √ √ √ 5 √
32 √ √ √ √ √ 5 √
33 √ √ √ √ √ 5 √
34 √ √ √ √ √ 5 √

Table 3

Correlation of domains between sCOPD-PRO scale and SGRQ"

Domain of sCOPD-PRO scale Domain of SGRQ
Symptoms Activities Impacts Total score
Lung and kidney deficiency symptoms 0.31** 0.62** 0.47** 0.58**
Spleen deficiency symptoms 0.20** 0.24** 0.30** 0.27**
Functional activities 0.34** 0.77** 0.52** 0.69**
Emotional impacts 0.37** 0.25** 0.51** 0.43**
Total score 0.37** 0.66** 0.59** 0.72**

Table 4

Discriminant validity of sCOPD-PRO scale ($\bar{x}$±s)"

Lung
function classification		 n Lung and kidney
deficiency symptoms		 Spleen deficiency
symptoms		 Functional
activities		 Emotional impacts Total score
Mild 16 36.20±17.40 26.56±17.60 32.50±18.60 38.13±19.05 33.35±15.18
Moderate 303 48.83±16.83 37.87±21.13 47.19±20.38 38.32±16.15 43.05±13.35
t value –2.92 –2.10 –2.82 –0.05 –2.81
P value 0.004 0.036 0.005 0.963 0.005

Table 5

Factor analysis of sCOPD-PRO scale"

Domain Item Factor 1 Factor 2 Factor 3 Factor 4
Functional activities
17 0.79 - - -
18 0.69 0.31 - -
19 0.71 0.20 - -
20 0.84 0.21 - -
21 0.73 0.35 - -
22 0.45 0.55 - -
23 0.64 0.50 - -
24 0.81 0.32 - -
25 0.64 0.30 - -
27 0.77
Lung and kidney deficiency symptoms
3 0.34 0.77 - -
4 0.39 0.78 - -
5 0.41 0.71 - -
6 0.52 - - 0.49
9 0.41 0.45 - -
10 0.65 0.22 - 0.29
Emotional impacts
30 - 0.33 0.65 -
31 - 0.37 0.66 0.26
32 0.47 - 0.67 -
33 - - 0.85 -
34 - - 0.81 0.24
Spleen deficiency symptoms
14 - - - 0.88
15 - - 0.34 0.77

Table 6

Comparison of sCOPD-PRO scale scores among groups before and after intervention"

Domain Group n Score (x±s) t value P value ES SRM
Before treatment After treatment Difference value
Lung and kidney deficiency symptoms
TCM 106 50.16±16.40 35.46±12.46 14.70±13.10 11.55 <0.001 0.90 1.12
Western medicine 106 47.56±15.77 38.01±13.74 9.55±10.45 9.41 <0.001 0.61 0.91
Placebo 107 46.88±18.82 44.31±25.08 2.57±14.19 1.87 0.064 0.14 0.18
Spleen deficiency symptoms
TCM 106 37.74±19.05 27.71±17.68 10.02±19.09 5.41 <0.001 0.53 0.52
Western medicine 106 35.38±18.21 26.89±14.90 8.49±15.19 5.75 <0.001 0.47 0.56
Placebo 107 38.78±25.29 38.55±29.25 0.23±17.84 0.14 0.893 0.01 0.01
Functional activities
TCM 106 47.92±20.45 39.58±17.13 8.35±9.93 8.65 <0.001 0.41 0.84
Western medicine group 106 47.10±20.25 40.97±18.03 6.13±10.48 6.02 <0.001 0.30 0.58
Placebo 107 44.34±20.87 43.06±22.87 1.29±11.83 1.12 0.264 0.06 0.11
Emotional impacts
TCM 106 39.58±15.49 32.03±12.38 7.55±10.94 7.10 <0.001 0.49 0.69
Western medicine 106 37.22±16.59 30.05±11.33 7.17±11.81 6.25 <0.001 0.43 0.61
Placebo 107 38.13±16.77 42.48±26.31 –4.35±18.42 –2.44 0.016 –0.26 –0.24
Total score
TCM 106 43.85±13.23 33.69±9.87 10.16±9.00 11.62 <0.001 0.77 1.13
Western medicine 106 41.81±12.36 33.98±8.93 7.84±8.69 9.29 <0.001 0.63 0.90
Placebo 107 42.04±15.05 42.10±22.18 –0.06±11.43 –0.06 0.954 0.00 –0.01
[1] Zhang HY, An L . Global initiative for chronic obstructive lung disease[J]. Zhongguo Yi Kan, 2002,37(2):44-47.
doi: 10.3969/j.issn.1008-1070.2002.02.026
张洪玉, 安立 . 慢性阻塞性肺疾病全球创议简介[J]. 中国医刊, 2002,37(2):44-47.
doi: 10.3969/j.issn.1008-1070.2002.02.026
[2] Group of Chronic Obstructive Pulmonary Disease,Chinese Society of Respiratory Diseases. Guideline for diagnosis and treatment of COPD(2007 revised edition)[J]. Ji Xu Yi Xue Jiao Yu, 2007,21(2):31-42
doi: 10.3969/j.issn.1004-6763.2007.02.008
中华医学会呼吸病学分会慢性阻塞性肺疾病学组. COPD诊治指南(2007年修订版)[J]. 继续医学教育, 2007,21(2):31-42
doi: 10.3969/j.issn.1004-6763.2007.02.008
[3] Huang DH, Wu L, He DP, Lin L . Clinical observation of tranquilization period of chronic obstructive pulmonary disease treated by integration of traditional Chinese medicine and Western medicine[J]. Di Si Jun Yi Da Xue Xue Bao, 2005,26(17):1611-1613
黄东晖, 吴蕾, 何德平, 林琳 . 中西医综合治疗慢性阻塞性肺疾病稳定期临床观察[J]. 第四军医大学学报, 2005,26(17):1611-1613
[4] Han H, Liu JB . Research on treatment of chronic obstructive pulmonary disease by Chinese medicine[J]. Jiangsu Zhong Yi Yao, 2008,40(6):93-94
韩慧, 刘建博 . 慢性阻塞性肺疾病的中医药治疗概况[J]. 江苏中医药, 2008,40(6):93-94
[5] Xu YH, Wang JH, Li HF, Zhu XH, Wang G . Efficacy of integrative respiratory rehabilitation training in exercise ability and quality of life of patients with chronic obstructive pulmonary disease in stable phase: a randomized controlled trial[J]. J Chin Integr Med, 2010,8(5):432-437
doi: 10.3736/jcim20100506
徐远红, 王俊华, 李海峰, 朱小虎, 王刚 . 中西医结合康复训练对慢性阻塞性肺疾病患者运动能力及生活质量的影响: 随机对照临床试验[J]. 中西医结合学报, 2010,8(5):432-437
doi: 10.3736/jcim20100506
[6] U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79
doi: 10.1186/1477-7525-4-79
[7] Celli BR, MacNee W ; ATS/ERS Task Force.Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper[J]. Eur Respir J, 2004,23(6):932-946
doi: 10.1183/09031936.04.00014304
[8] Jones PW, Baveystock CM, Littlejohns P . Relationships between general health measured with the sickness impact profile and respiratory symptoms, physiological measures, and mood in patients with chronic airflow limitation[J]. Am Rev Respir Dis, 1989,140(6):1538-1543
doi: 10.1164/ajrccm/140.6.1538
[9] Jones PW, Quirk FH, Baveystock CM, Littlejohns P . A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire[J]. Am Rev Respir Dis, 1992,145(6):1321-1327
doi: 10.1164/ajrccm/145.6.1321
[10] Lu WX, Zhang YJ, Hu B, Ma Y, Zhu YJ . Application of St George’s respiratory questionnaire in evaluating the life quality of Chinese patients with chronic obstructive pulmonary disease[J]. Zhonghua Jie He He Hu Xi Za Zhi, 2003,26(4):195-198
陆慰萱, 张一杰, 胡波, 马毅, 朱元珏 . 应用St George’s呼吸问卷评价我国慢性阻塞性肺疾病患者生活质量的价值[J]. 中华结核和呼吸杂志, 2003,26(4):195-198
[11] Ware JE, Snow KK, Kosisnki M, Gandek B . SF-36 health survey manual and interpretation guide[M]. Boston: The Health Institute, 1993
[12] Zhu YB. Measurement and evaluation of quality of life[M]. Beijing: People’s Military Medical Press, 2010: 55-75
朱燕波 . 生命质量( QOL)测量与评价[M]. 北京: 人民军医出版社, 2010: 55-75
[13] Chen XL, Liu FB, Guo L, Liu XB . Development of patient-reported outcome scale for myasthenia gravis: a psychometric test[J]. J Chin Integer Med, 2010,8(2):121-125
陈新林, 刘凤斌, 郭丽, 刘小斌 . 重症肌无力患者报告结局指标量表的研制——计量心理学测评[J]. 中西医结合学报, 2010,8(2):121-125
[14] Wan CH. Determination and application of the quality of life of cancer patients[M]. Beijing: Science Press, 2007: 98
万崇华 . 癌症患者生命质量测定与应用[M]. 北京: 科学出版社, 2007: 98
[15] Husted JA, Cook RJ, Farewell VT, Gladman DD . Methods for assessing responsiveness: a critical review and recommendations[J]. J Clin Epidemiol, 2000,53(5):459-468
doi: 10.1016/S0895-4356(99)00206-1
[1] Fu-feng Li, Jie Zhao, Peng Qian, Yi-qin Wang, Jing-jing Fu, Zhu-mei Sun, Hai-xia Yan, Li Yang. Metabolite changes in the greasy tongue coating of patients with chronic gastritis. Journal of Chinese Integrative Medicine, 2012, 10(7): 757-765.
[2] Na Mu-hai, Yao Cheng-zeng, Yu Xiao-tian, Jiang Mei-xian. Effects of added therapy with Chinese herbal medicine Kanli Granule on skeletal muscle dysfunction in patients with chronic heart failure. Journal of Chinese Integrative Medicine, 2012, 10(3): 324-329.
[3] Liang-ping Hu, Xiao-lei Bao, Qi Wang . The control principle in scientific research. Journal of Chinese Integrative Medicine, 2011, 9(8): 834-.
[4] Zheng-kun Hou, Feng-bin Liu, Ying-yu Liang, Kun-hai Zhuang, Chu-hua Lin, Li-juan Li . On the necessity of developing quality of life instruments in traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2011, 9(5): 468-482.
[5] Jun-lin Hu, Gui-lin Ouyang, Da-peng Han, Qing Xia, Yong He, Zheng Huang, Fei Zhu, Song-tao Sun. Effects of Tuina and Chinese patent drug Shuxuetong injection on deep venous thrombosis and functional rehabilitation after total knee arthroplasty. Journal of Chinese Integrative Medicine, 2011, 9(10): 1088-1093.
[6] Ni-da Cao, Ai-guang Zhao, Jin-kun Yang. Survival time of advanced gastric cancer patients treated with integrated traditional Chinese and Western medicine therapy. Journal of Chinese Integrative Medicine, 2010, 8(2): 116-120.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)". Journal of Chinese Integrative Medicine, 2008, 6(1): 15-21
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[4] Wei Zhang, Xiang-feng Lu, Xiao-mei Zhang, Jian-jun Wu, Liang-duo Jiang. A rat model of pulmonary fibrosis induced by infusing bleomycin quickly through tracheal intubation. Journal of Chinese Integrative Medicine, 2008, 6(1): 60-67
[5] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[6] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[7] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[8] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[9] Xin-jun Wang, Ling-ling Wang . A mechanism of endogenous opioid peptides for rapid onset of acupuncture effect in treatment of depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1014-1017
[10] Bo Wang , Wei Yan , Li-hui Hou, Xiao-ke Wu. Disorder of Tiangui (kidney essence) and reproductive dysfunction in patients with polycystic ovary syndrome. Journal of Chinese Integrative Medicine, 2010, 8(11): 1018-1022
[an error occurred while processing this directive]